ESMO 2023 Highlights: Early-Stage NSCLC, SCLC, Thymic Carcinoma

Part 2 of our podcast coverage on ESMO 2023 includes an in-depth interview with Dr. Jarushka Naidoo on early-stage NSCLC, including updates from CHECKMATE 816, KEYNOTE 671 overall survival results, and Checkmate77T, first perceptions about the data, remaining unanswered questions and how to incorporate to our clinical practice. Further, we discussed exciting data in the 2nd line setting for Small-Cell Lung Cancer and a new potential therapeutic option for thymic carcinoma. Tune in for this thought-provoking, data-driven, and practical episode of Lung Cancer Considered.